CN104379214A - Kudzu and phytosterols for use in the treatment of metabolic disorders - Google Patents
Kudzu and phytosterols for use in the treatment of metabolic disorders Download PDFInfo
- Publication number
- CN104379214A CN104379214A CN201380033325.3A CN201380033325A CN104379214A CN 104379214 A CN104379214 A CN 104379214A CN 201380033325 A CN201380033325 A CN 201380033325A CN 104379214 A CN104379214 A CN 104379214A
- Authority
- CN
- China
- Prior art keywords
- compositions
- purposes
- aforementioned
- plant sterol
- gelsemii elegantis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention generally relates to the field of health and wellness. In particular, the present invention addresses metabolic disorders and disorders associated therewith. For example, the present invention describes a composition comprising phytosterols and kudzu for use in the treatment, alleviation or prevention of metabolic disorders.
Description
Generally, the present invention relates to health and health field.Specifically, the invention solves metabolism disorder and relative disorder.Such as, the invention describes the compositions comprising plant sterol (phytosterols) and Herba Gelsemii Elegantis (Kudzu) being used for the treatment of, alleviating or preventing metabolism disorder.
Many decades in the past, the popular of obesity is increased to epidemic proportions in the whole world.The whole world about 1,000,000,000 people is overweight or fat, and this is the situation improving mortality rate, flowing and Financial cost.Develop into obesity when Energy intaking is greater than energy expenditure, excess energy mainly as fat stores in fatty tissue.Can by reducing Energy intaking or reducing bioavailability, increase energy expenditure and/or the storage that reduces as fat and reach and lose weight and prevent body weight to increase.Obesity represents serious health threat because it to a series of chronic disease, to comprise diabetes, atherosclerosis, neuodegenerative disorder, airway disorders and certain cancers relevant.
Well-known Herba Gelsemii Elegantis and plant sterol have useful health benefit; But these two kinds of single compositions have their limitation.
Herba Gelsemii Elegantis (Radix Pueraria) is the abundant source of isoflavone glucoside, convention is used for the treatment of alcoholism, diabetes, gastroenteritis and deafness.The abundantest Herba Gelsemii Elegantis isoflavone is puerarin (daidzein 8-C-glucoside).Its complex is also containing daidzein, daidzin (daidzein 7-O-glucoside) and other isoflavone.Original observed result is that puerarin reduces in hepatocyte instead of apolipoprotein (ApoB100) secretion (people such as Lee in enterocyte system, 2002 (Lee JS, Deng people, BMC ComplementAltern Med.2002 December 16 days; 2:12.2002 electronic edition).
Although Herba Gelsemii Elegantis is considered to use safe usually, in few case, report undesired side effect.These side effect can for oral edible after allergy to slowing down blood coagulation and other therapeutic treatment may be disturbed.
Therefore, for the purpose of careful, suggestion keeps alap Herba Gelsemii Elegantis dosage.
When using with low dosage to avoid this kind of rare undesired side effect, find that Herba Gelsemii Elegantis reduces for blood fat or cholesterol the effect not having statistically significant.
Known plants sterol can reduce the haemoconcentration of T-CHOL and LDL-C by the cholesterol absorption reduced in intestinal.The daily intake of about 2.4g phytosterol (plant sterols) (or its saturated form stanol (stanols)) reduces 8% along with T-CHOL haemoconcentration.Also there is plant sterol may to the more effective instruction of diabetes tool (Five Phytosterols from Aloe VeraGel as Anti-diabetic Compounds; The people such as Tanaka, Biological andPharmaceutical Bulletin Vol.29 (2006), No.71418).But if used with significant quantity, plant sterol has undesired side effect.Such as, their suppression α and bata-carotene absorptions known.Bata-carotene is the important sources of vitamin A, and vitamin A is required for such as g and D.
When to avoid the low dosage of remarkable undesired side effect to use, phytosterol to metabolism disorder as obesity does not have the effect of statistically significant.
But this area has no side effect for using safely and the natural medicine that can reduce the risk occurring metabolism disorder has clear and definite needs.
The present inventor has solved these needs.
Therefore, the object of the invention is to improve prior art state, the natural composition overcoming prior art problem and solve above-mentioned needs is particularly provided.
The present inventor surprisingly finds, the theme of independent claims achieves object of the present invention.The theme of dependent claims has further developed central idea of the present invention.
Specifically, the present inventor finds in Hamster model: when using together, Herba Gelsemii Elegantis and plant sterol are worked in coordination with and are played a role, allow statistically to reduce blood fat significantly, reduce body weight increase and athero, keep the respective dosage of plant sterol and Herba Gelsemii Elegantis enough low to avoid undesired side effect and discomfort simultaneously.
Therefore, the present invention partly relates to the compositions comprising plant sterol and Herba Gelsemii Elegantis being used for the treatment of, alleviating or preventing metabolism disorder.
The invention still further relates to plant sterol and Herba Gelsemii Elegantis for the preparation for the treatment of, alleviate or prevent the purposes in the compositions of metabolism disorder.
It is very effective that the combination of Herba Gelsemii Elegantis and plant sterol is proved to be in preventing hyperlipidemia concentration from increasing, particularly when edible high fat diet.
For the purposes of the present invention, if fat content ratio recommended intake every day (RDI) height at least 10%, at least 25%, at least 50%, at least 75% or at least 100% of diet, then this diet is considered to " higher fatty acid ".
Therefore, the metabolism disorder that can prevent, improve or treat by compositions of the present invention can be relevant to hypertriglyceridemia.
Such as, described metabolism disorder can be selected from overweight, obesity, diabetes, hypertension, liver cirrhosis, metabolism syndrome and combination thereof.
" overweight " is defined as the BMI with 25-30 for adult.
" Body Mass Index " or " BMI " refer in the body weight of kg divided by the height of rice square ratio.
" obesity " is following situation: be stored in animal, particularly people and the natural energy deposit in other mammiferous fatty tissue and be increased to the point relevant to the mortality rate of some health status or increase." obesity " is defined as the BMI having and be greater than 30 for adult.
For developing for further metabolism disorder, particularly importantly high body weight, particularly fat mass increase.
Therefore, preventing or treat overweight and/or obesity is an important application of the present invention.
The present inventor can confirm: compositions of the present invention can be used for the accumulation preventing or reduce excessive perinephric fat.
Therefore, compositions of the present invention can be used for reducing or prevention perinephric fat: the rising of body weight ratio.
When edible high fat diet, this is useful especially.
Perinephric fat thickness is also chronic nephropathy in type 2 diabetes mellitus patient, kidney resistance index raises and independent predictor people such as (, Nephrol.Dial.Transplant. (2011) 26 (3): 892-898) lamacchia of hyperuricemia.Therefore, compositions of the present invention also can be used for treatment or prevents these diseases.
The present inventor also has been found that: the accumulation that compositions of the present invention can be used particularly well in prevention or slim the abdomen.
Therefore, said composition can be used for reducing or prevention stomach fat: the rising of body weight ratio.
Stomach fat can be the interior fat around abdomen organ or the subcutaneous fat between skin and stomach wall.
Compositions of the present invention has effect to interior fat and subcutaneous fat.
Although well-known interior fat is that the primary fat as relevant in insulin resistant to Risk factors deposits, but latest result also shows that subcutaneous fat also can participate in this kind of risk factor, particularly (the people such as Goodpaster in people, Diabetes, in October, 1997,46th volume the 10th phase, 1579-1585).
Simultaneously, obesity and the relation of risk developing into noninsulindependent diabetes (NIDDM), hypertension and the cardiovascular disease are well established (people such as Smith, Metabolism, the 50th volume the 4th phase (April), calendar year 2001: 425-435 page); Therefore, compositions of the present invention also can be used for treatment or prevents these diseases.
And for the individuality not suffering from metabolism disorder, compositions of the present invention also can be useful.They such as can be used for support weight management.
Weight management can be of value to and keep or improve individuality to its outward appearance and healthy satisfaction.
Weight management also can be regarded as the prevention of risk measure reducing and suffer from metabolism disorder.
Therefore, compositions of the present invention may be used for support weight management.
In treatment use, compositions is to be enough to cure diseases and/or its complication or stop the amount of its symptom to be used at least in part.The amount being enough to realize this is defined as " treatment effective dose ".Effectively measure for this object and will depend on many factors well known by persons skilled in the art, the body weight of such as disease severity and patient and general state.
In prophylactic applications, compositions of the present invention is applied to the patient easily suffering from specified disease or be in addition in specified disease risk with the amount being enough to reduce at least in part the risk developing into disease.This amount is defined as " prevention effective dose ".Such as, and precise volume depends on multiple patient's specific factor, the health status of patient and body weight.
According to dose-effect curve, compositions of the present invention is effective.They can to treat effective dose or to prevent effective dose to use.Those skilled in the art can suitably determine this dosage.
But usually, compositions of the present invention can be used with the daily dose being equivalent to every kg body weight every day at least 0.04g, 0.6g, 3g, 6g, 10g or 80g Herba Gelsemii Elegantis and at least 2.5mg, 10mg, 15mg, 25mg or 40mg plant sterol.
Such as, compositions of the present invention can comprise at least 0.04g Herba Gelsemii Elegantis and at least 2.5mg plant sterol/kg body weight/day.
Or compositions of the present invention can comprise at least 3g Herba Gelsemii Elegantis and at least 15mg plant sterol/kg body weight/day.
Also or, compositions of the present invention can comprise at least 6g Herba Gelsemii Elegantis and at least 40mg plant sterol/kg body weight/day.
In order to avoid undesired side effect as spoiled or vitamin A absorption suppress, dosage should remain on rational low-level.
Such as, the dosage of Herba Gelsemii Elegantis can not more than 6g/kg body weight/day, and the dosage of plant sterol can not more than 40mg/kg body weight/day.
Herba Gelsemii Elegantis can provide with the form being suitable for arbitrarily being applied to human or animal.Such as, Herba Gelsemii Elegantis as Radix Puerariae, Herba Gelsemii Elegantis leaf, Flos Pueraria omeiensis, dry Herba Gelsemii Elegantis or can provide as its extract.
Extract can be such as water extract.Water extract has following advantage: before extract may be used for human or animal's consumption, do not have solvent must remove from extract.
The typical plant sterol of object used in the present invention can be selected from phytosterol, stanol or its combination.
Example has cupreol, campesterol and/or stigmasterol.
Plant sterol can be used as chemical pure compound and provides.So, they can from plant origin purification or chemosynthesis.Can realize point-device administration like this.
Plant sterol from natural origin or its extract also can be preferably provided.So, plant sterol can be meals plant sterol.They as vegetable oil, nut, cereal products, veterinary antibiotics, berry or can provide as its extract.
Compositions can be the arbitrary composition being suitable for human or animal's consumption.
So, compositions can be selected from food product, beverage, functional food, dietetic product, food additive, age and pet food.
Because metabolism disorder not only occurs but also also occurs in animal, so compositions of the present invention can be used for being applied to human or animal, such as companion animals as cat or Canis familiaris L. in people.
Advantageously, compositions of the present invention can be applied before closing on consumption high fat diet, with it simultaneously or after consumption high fat diet soon.
So, compositions 1 littlely can be used before high fat diet in the time range of 1 hour afterwards.
It will be understood by those skilled in the art that they freely can combine all features of the present invention as herein described and not deviate from disclosed invention scope.Especially, can be applied to compositions of the present invention to the feature described in purposes of the present invention, vice versa.
Other advantage of the present invention and feature are apparent from following embodiment and accompanying drawing.
The combined therapy of Herba Gelsemii Elegantis and phytosterol that Fig. 1 shows same dose causes the perinephric fat of HFD hamster to increase significantly and synergistically and obviously reduces.Pass through Tukey ' s multiple comparative test by one way analysis of variance, subsequently and do not match Student t check analysis data.Meansigma methods ± SEM, n=8-12, * P<0.05, in contrast to contrast;
p < 0.05, in contrast to HFD placebo.
The combined therapy of Herba Gelsemii Elegantis and phytosterol that Fig. 2 shows same dose causes the stomach fat of HFD hamster to increase significantly and synergistically and obviously reduces.Pass through Tukey ' s multiple comparative test by one way analysis of variance, subsequently and do not match Student t check analysis data.Meansigma methods ± SEM, n=8-12, * P<0.05, in contrast to contrast;
in contrast to HFD placebo.
Embodiment
The Syria hamster (Golden Syrianhamster) of heavily about 120-130g is buied from Beijing Vital River Experimental Animals Technology Co., Ltd. (Vital River LaboratoryAnimal Co., Ltd).By animal feeding at controlled environment (22-24 DEG C dark with the bright-12h of 12h), freely drink water and take food.
After adapting to 1 week, hamster is randomized into different tests group.By bringing out hyperlipemia to detoxification High cholesterol diet, and determined by plasma TC, the rising of TG and HDL-C content.Diet is by obtaining following compositions mixing (g/kg):
Component powders and gelatin solution (20g/L) are mixed with the ratio of 200g diet/rise solution.Once gelatin solidifies, diet is cut into cubical piece of about 10g, for subsequent use in-80 DEG C of refrigerated storages.
Test group is as follows:
1) contrast: normal diet group (n=12)
2) HFD: high-fat diet group (n=12)
3) HFD-K: the Radix Puerariae extract (3g/kg/ days, n=12) in high fat diet
4) HFD-PS: the phytosterol ester (phytosterol ester 0.15g/kg/ days, n=12) 5 in high fat diet) HFD-PS/K: the phytosterol ester in high fat diet and kudzu root extract (n=12)
1. plant sterol (PS) and Radix Puerariae (K) synergism that fatty tissue is reduced.
Excess body weight is relevant with osteoarthritis with the cancer of various diseases, particularly cardiovascular disease, type 2 diabetes mellitus, obstructive sleep apnea, some type.Therefore, have been found that obesity decreases life expectancy.
1.1 perinephric fats: after processing 8 weeks, high fat diet significantly increases perinephric fat: the ratio (table 1, HFD-placebo in contrast to contrast) of body weight.Compared with HFD placebo, process to body weight not significantly change effect with independent plant sterol or Radix Puerariae water extract that (Fig. 1, HFD-K, HFD-PS in contrast to contrast, * P < 0.05 simultaneously; HFD-K, HFD-PS in contrast to HFD-placebo, P > 0.05).Although two kinds Body components do not demonstrate significant protective effect separately; but the Radix Puerariae of same dose significantly reduces perinephric fat with the combined treatment of phytosterol compared with HFD-placebo: ratio (Fig. 1 of body weight; HFD-PS/K in contrast to HFD placebo
).
The perinephric fat minimizing effect of table 1. Radix Puerariae (K) water extract and plant sterol (PS) in high fat diet (HFD) hamster
1.2 stomach fats: after processing 8 weeks, high fat diet significantly increases stomach fat and stomach fat: the ratio (table 2, HFD-placebo in contrast to contrast) of body weight.Compared with HFD placebo, process to body weight not significantly change effect with plant sterol or Radix Puerariae water extract that (Fig. 2, HFD-K, HFD-PS in contrast to contrast, * P < 0.05 simultaneously; HFD-K, HFD-PS in contrast to HFD-placebo, P > 0.05).Although two kinds Body components do not demonstrate significant protective effect separately; but the Radix Puerariae of same dose significantly reduces stomach fat with the combined treatment of phytosterol compared with HFD-placebo: ratio (Fig. 2 of body weight; HFD-PS/K in contrast to HFD placebo
).The stomach fat minimizing effect of table 2. Radix Puerariae (K) water extract and plant sterol (PS) in high fat diet (HFD) hamster
Claims (15)
1. be used for the treatment of, alleviate or prevent the compositions comprising plant sterol and Herba Gelsemii Elegantis of the purposes of metabolism disorder.
2. the compositions for purposes according to claim 1, wherein said metabolism disorder is relevant to hypertriglyceridemia.
3., according to the compositions for purposes of one of aforementioned claim, wherein said metabolism disorder is selected from overweight, obesity, diabetes, hypertension, liver cirrhosis, metabolism syndrome and combination thereof.
4. according to the compositions for purposes of one of aforementioned claim, for reducing or prevention perinephric fat: the rising of body weight ratio.
5. according to the compositions for purposes of one of aforementioned claim, for reducing or prevention stomach fat: the rising of body weight ratio.
6. according to the compositions for purposes of one of aforementioned claim, for support weight management.
7., according to the compositions for purposes of one of aforementioned claim, wherein said compositions is used with the daily dose being equivalent to every kg body weight every day at least 0.04g, 0.6g, 3g, 6g, 10g or 80g Herba Gelsemii Elegantis and at least 2.5mg, 10mg, 15mg, 25mg or 40mg plant sterol.
8., according to the compositions for purposes of one of aforementioned claim, wherein Herba Gelsemii Elegantis is as Radix Puerariae, Herba Gelsemii Elegantis leaf, Flos Pueraria omeiensis, dry Herba Gelsemii Elegantis or provide as its extract.
9. the compositions for purposes according to claim 8, wherein said extract is water extract.
10., according to the compositions for purposes of one of aforementioned claim, wherein said plant sterol is selected from phytosterol and stanol; Such as cupreol, campesterol and stigmasterol.
11. according to the compositions for purposes of one of aforementioned claim, and wherein said plant sterol is meals plant sterols, and as vegetable oil, nut, cereal products, veterinary antibiotics, berry or provide as its extract.
The compositions for purposes of one of 12. aforementioned claim, wherein said compositions is selected from food product, beverage, functional food, dietetic product, food additive, age and pet food.
13. according to the compositions for purposes of one of aforementioned claim, and wherein said compositions will be applied to adult or old people.
14. according to the compositions for purposes of one of aforementioned claim, and wherein said compositions will be applied to human or animal, such as companion animals as cat or Canis familiaris L..
15. according to the compositions for purposes of one of aforementioned claim, and wherein said compositions 1 littlely will to be used before high fat diet in the time range of 1 hour afterwards.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201380033325.3A CN104379214A (en) | 2012-07-23 | 2013-07-22 | Kudzu and phytosterols for use in the treatment of metabolic disorders |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2012/079048 WO2014015467A1 (en) | 2012-07-23 | 2012-07-23 | Composition comprising phytosterols and kudzu and its use in the treatment, alleviation or prevention of metabolic disorders |
| CNPCT/CN2012/079048 | 2012-07-23 | ||
| CN201380033325.3A CN104379214A (en) | 2012-07-23 | 2013-07-22 | Kudzu and phytosterols for use in the treatment of metabolic disorders |
| PCT/EP2013/065450 WO2014016266A1 (en) | 2012-07-23 | 2013-07-22 | Kudzu and phytosterols for use in the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104379214A true CN104379214A (en) | 2015-02-25 |
Family
ID=52557523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380033325.3A Pending CN104379214A (en) | 2012-07-23 | 2013-07-22 | Kudzu and phytosterols for use in the treatment of metabolic disorders |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104379214A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109513006A (en) * | 2018-12-18 | 2019-03-26 | 江苏大学附属医院 | It is a kind of to treat metabolic syndrome morbidity drug and its measuring method |
| CN111004336A (en) * | 2020-03-09 | 2020-04-14 | 江西中医药大学 | Kudzu root polysaccharide and preparation method and application thereof |
| CN116076640A (en) * | 2021-11-08 | 2023-05-09 | 莒南和信食品有限公司 | Application and process of beta-sitosterol in beverage |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070106304A (en) * | 2006-04-28 | 2007-11-01 | 주식회사 삼양제넥스 | Composition containing water-dispersed phytosterol ester |
-
2013
- 2013-07-22 CN CN201380033325.3A patent/CN104379214A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070106304A (en) * | 2006-04-28 | 2007-11-01 | 주식회사 삼양제넥스 | Composition containing water-dispersed phytosterol ester |
Non-Patent Citations (3)
| Title |
|---|
| 南京中医药大学: "《中药大辞典》", 31 March 2006, 上海科学技术出版社 * |
| 唐传核: "《植物生物活性物质》", 31 January 2005, 化学工业出版社 * |
| 杨月欣等: "《营养功能成分应用指南》", 30 June 2011, 北京大学医学出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109513006A (en) * | 2018-12-18 | 2019-03-26 | 江苏大学附属医院 | It is a kind of to treat metabolic syndrome morbidity drug and its measuring method |
| CN111004336A (en) * | 2020-03-09 | 2020-04-14 | 江西中医药大学 | Kudzu root polysaccharide and preparation method and application thereof |
| CN116076640A (en) * | 2021-11-08 | 2023-05-09 | 莒南和信食品有限公司 | Application and process of beta-sitosterol in beverage |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mohamed et al. | Natural anti-obesity agents | |
| JP2011509989A5 (en) | ||
| Deng | Food and food supplements with hypocholesterolemic effects | |
| CN106729092A (en) | A kind of blood fat reducing preparation containing xylo-oligosaccharide and its preparation method and application | |
| CN107467497A (en) | A kind of five cereals food therapeutic composition with anti-adiposity health care function and preparation method thereof | |
| CN105126067A (en) | Composition for reducing uric acid and application thereof | |
| CN104435257A (en) | Composition conducive to lowering of cholesterol, and preparation method, preparation and application of composition | |
| CN104138469A (en) | Medicinal composite preparation for treating type 2 diabetes and reversing insulin resistance, and preparation method thereof | |
| CN104379214A (en) | Kudzu and phytosterols for use in the treatment of metabolic disorders | |
| WO2013087023A1 (en) | Natural weight reduction health composition and application thereof | |
| JP2015533138A (en) | Formulations for treating and preventing obesity | |
| CN105851360A (en) | Preparation method for health food capable of substantially improving blood sugar and blood fat and rapidly supplementing trace elements essential for human body | |
| CN102526346B (en) | Health-care pharmaceutical formulation with immunity-enhancing and senility-delaying functions | |
| Nieman | Quercetin's bioactive effects in human athletes. | |
| CN104411319A (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| CN106728108A (en) | A kind of hypertension and hyperlipemia Chinese medicine composition containing gynostemma pentaphylla | |
| He et al. | Combined lowering effect of phytosterol esters and tea extracts on lipid profiles in SD rats | |
| WO2014016265A1 (en) | Hawthorn and phytosterols and their effect on metabolic disorders | |
| KR101952648B1 (en) | The Inhibitory Effects of Amomum vilosum Loureiro Extracts and Composition Containing the Extract as Effective Ingredient | |
| WO2014016266A1 (en) | Kudzu and phytosterols for use in the treatment of metabolic disorders | |
| JP2010030950A (en) | Prophylactic and therapeutic agent for metabolic syndrome and functional food | |
| WO2013117007A1 (en) | Composition comprising phytosterols and kudzu for cardiovascular diseases | |
| WO2013117731A1 (en) | Hawthorn and kudzu and their effect on cardiovascular diseases | |
| KR100532556B1 (en) | Composition for treating obesity and constipation containing extract of pine needle, green tea and black tea as an active ingredient | |
| CN110101745A (en) | A kind of pharmaceutical composition for treating and/or inhibiting nonalcoholic fatty liver to develop |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190705 Address after: Vevey Applicant after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Applicant before: Nestle Products Technical Assistance Co., Ltd. |
|
| TA01 | Transfer of patent application right | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150225 |
|
| WD01 | Invention patent application deemed withdrawn after publication |